What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FibroGen (NASDAQ: FGEN) received some bad news recently with an overwhelmingly negative vote by a U.S. Food and Drug Administration (FDA) advisory committee related to anemia drug roxadustat. In this Motley Fool Live video recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss what's next for FibroGen after this disappointing vote.
Source Fool.com